NASDAQ:DSGN

Design Therapeutics Competitors

$26.38
-1.93 (-6.82 %)
(As of 05/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.04
$28.06
50-Day Range
$19.02
$41.49
52-Week Range
$18.81
$50.50
Volume33,499 shs
Average Volume180,235 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Design Therapeutics (NASDAQ:DSGN) Vs. VZIO, DOCN, SEMR, NAPA, TDUP, and PLBY

Should you be buying DSGN stock or one of its competitors? Companies in the industry of "--" are considered alternatives and competitors to Design Therapeutics, including VIZIO (VZIO), DigitalOcean (DOCN), SEMrush (SEMR), The Duckhorn Portfolio (NAPA), ThredUp (TDUP), and PLBY Group (PLBY).

Design Therapeutics (NASDAQ:DSGN) and VIZIO (NYSE:VZIO) are both -- companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and target prices for Design Therapeutics and VIZIO, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Design Therapeutics01202.67
VIZIO00703.00

Design Therapeutics currently has a consensus target price of $35.3333, suggesting a potential upside of 33.94%. VIZIO has a consensus target price of $30.00, suggesting a potential upside of 9.45%. Given Design Therapeutics' higher probable upside, analysts clearly believe Design Therapeutics is more favorable than VIZIO.

Earnings & Valuation

This table compares Design Therapeutics and VIZIO's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Design TherapeuticsN/AN/AN/AN/AN/A
VIZION/AN/AN/AN/AN/A

Profitability

This table compares Design Therapeutics and VIZIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Design TherapeuticsN/AN/AN/A
VIZION/AN/AN/A

Summary

VIZIO beats Design Therapeutics on 2 of the 3 factors compared between the two stocks.

Design Therapeutics (NASDAQ:DSGN) and DigitalOcean (NASDAQ:DOCN) are both -- companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Earnings and Valuation

This table compares Design Therapeutics and DigitalOcean's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Design TherapeuticsN/AN/AN/AN/AN/A
DigitalOceanN/AN/AN/AN/AN/A

Profitability

This table compares Design Therapeutics and DigitalOcean's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Design TherapeuticsN/AN/AN/A
DigitalOceanN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Design Therapeutics and DigitalOcean, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Design Therapeutics01202.67
DigitalOcean02802.80

Design Therapeutics currently has a consensus target price of $35.3333, indicating a potential upside of 33.94%. DigitalOcean has a consensus target price of $58.30, indicating a potential upside of 52.14%. Given DigitalOcean's stronger consensus rating and higher probable upside, analysts plainly believe DigitalOcean is more favorable than Design Therapeutics.

Summary

DigitalOcean beats Design Therapeutics on 3 of the 3 factors compared between the two stocks.

SEMrush (NASDAQ:SEMR) and Design Therapeutics (NASDAQ:DSGN) are both -- companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares SEMrush and Design Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SEMrushN/AN/AN/AN/AN/A
Design TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for SEMrush and Design Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SEMrush03302.50
Design Therapeutics01202.67

SEMrush currently has a consensus price target of $19.75, indicating a potential upside of 11.27%. Design Therapeutics has a consensus price target of $35.3333, indicating a potential upside of 33.94%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Design Therapeutics is more favorable than SEMrush.

Profitability

This table compares SEMrush and Design Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SEMrushN/AN/AN/A
Design TherapeuticsN/AN/AN/A

Summary

Design Therapeutics beats SEMrush on 2 of the 3 factors compared between the two stocks.

The Duckhorn Portfolio (NYSE:NAPA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap -- companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares The Duckhorn Portfolio and Design Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Duckhorn PortfolioN/AN/AN/A
Design TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares The Duckhorn Portfolio and Design Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Duckhorn PortfolioN/AN/AN/AN/AN/A
Design TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for The Duckhorn Portfolio and Design Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Duckhorn Portfolio02702.78
Design Therapeutics01202.67

The Duckhorn Portfolio currently has a consensus price target of $20.7778, suggesting a potential upside of 22.29%. Design Therapeutics has a consensus price target of $35.3333, suggesting a potential upside of 33.94%. Given Design Therapeutics' higher probable upside, analysts clearly believe Design Therapeutics is more favorable than The Duckhorn Portfolio.

Summary

The Duckhorn Portfolio beats Design Therapeutics on 2 of the 3 factors compared between the two stocks.

Design Therapeutics (NASDAQ:DSGN) and ThredUp (NASDAQ:TDUP) are both small-cap -- companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares Design Therapeutics and ThredUp's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Design TherapeuticsN/AN/AN/AN/AN/A
ThredUpN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Design Therapeutics and ThredUp, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Design Therapeutics01202.67
ThredUp01702.88

Design Therapeutics presently has a consensus price target of $35.3333, suggesting a potential upside of 33.94%. ThredUp has a consensus price target of $19.8571, suggesting a potential upside of 2.83%. Given Design Therapeutics' higher probable upside, analysts plainly believe Design Therapeutics is more favorable than ThredUp.

Profitability

This table compares Design Therapeutics and ThredUp's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Design TherapeuticsN/AN/AN/A
ThredUpN/AN/AN/A

Summary

ThredUp beats Design Therapeutics on 2 of the 3 factors compared between the two stocks.

PLBY Group (NASDAQ:PLBY) and Design Therapeutics (NASDAQ:DSGN) are both small-cap -- companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares PLBY Group and Design Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PLBY GroupN/AN/AN/AN/AN/A
Design TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for PLBY Group and Design Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PLBY Group00303.00
Design Therapeutics01202.67

PLBY Group currently has a consensus target price of $32.6667, suggesting a potential downside of 29.34%. Design Therapeutics has a consensus target price of $35.3333, suggesting a potential upside of 33.94%. Given Design Therapeutics' higher possible upside, analysts clearly believe Design Therapeutics is more favorable than PLBY Group.

Profitability

This table compares PLBY Group and Design Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PLBY GroupN/AN/AN/A
Design TherapeuticsN/AN/AN/A

Summary

PLBY Group beats Design Therapeutics on 2 of the 3 factors compared between the two stocks.


Design Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
VZIO
VIZIO
1.5$27.41-2.9%$5.04 billionN/A0.00Earnings Announcement
Gap Down
DOCN
DigitalOcean
2.0$38.32-0.2%$4.04 billionN/A0.00
SEMR
SEMrush
1.5$17.75-1.4%$2.39 billionN/A0.00Gap Down
NAPA
The Duckhorn Portfolio
1.4$16.99-3.3%$1.95 billionN/A0.00
TDUP
ThredUp
1.4$19.31-5.6%$1.75 billionN/A0.00Gap Down
PLBY Group logo
PLBY
PLBY Group
1.1$46.23-5.7%$1.56 billionN/A0.00High Trading Volume
Gap Down
TBA
Thoma Bravo Advantage
0.0$10.11-0.3%$1.04 billionN/A0.00
Apria logo
APR
Apria
1.4$28.72-0.7%$1.01 billionN/A0.00Upcoming Earnings
Analyst Upgrade
FTCI
FTC Solar
0.3$11.70-3.0%$995.20 millionN/A0.00
Bioventus logo
BVS
Bioventus
1.4$15.75-5.4%$894.99 millionN/A0.00Analyst Downgrade
IKNA
Ikena Oncology
1.7$19.74-13.1%$682.77 millionN/A0.00
CCV
Churchill Capital Corp V
0.0$9.93-0.9%$620.63 millionN/A0.00News Coverage
Adagene logo
ADAG
Adagene
1.5$13.08-9.8%$569.22 millionN/A0.00High Trading Volume
News Coverage
Gap Down
CTOS
Custom Truck One Source
0.8$10.66-1.3%$522.70 millionN/A0.00Gap Down
FWAA
Fifth Wall Acquisition Corp. I
0.0$10.72-1.7%$412.27 millionN/A0.00
LVTX
Lava Therapeutics B.V.
1.7$14.66-9.7%$371.66 millionN/A0.00High Trading Volume
Gap Up
SVFC
SVF Investment Corp. 3
0.3$10.03-1.7%$360.68 millionN/A0.00
UTME
United Time Technology
0.0$33.97-6.3%$280.86 millionN/A0.00Quiet Period Expiration
SVFB
SVF Investment Corp. 2
0.3$10.04-1.4%$258.03 millionN/A0.00High Trading Volume
VHAQ
Viveon Health Acquisition
0.0$9.92-0.6%$249.55 millionN/A0.00
HCAQ
HealthCor Catalio Acquisition
0.0$9.87-0.1%$204.31 millionN/A0.00
WNW
Wunong Net Technology
0.0$7.23-1.8%$180.75 millionN/A0.00Gap Down
RACB
Research Alliance Corp. II
0.0$10.71-0.0%$178.96 millionN/A0.00
ARYD
ARYA Sciences Acquisition Corp IV
0.0$10.44-3.1%$174.37 millionN/A0.00Gap Down
LBPS
4D pharma
1.0$10.53-4.5%$173.04 millionN/A0.00Upcoming Earnings
Gap Down
ABGI
ABG Acquisition Corp. I
0.0$9.91-0.6%$166.86 millionN/A0.00
Biophytis logo
BPTS
Biophytis
0.0$12.70-2.4%$143.68 millionN/A0.00
Vivos Therapeutics logo
VVOS
Vivos Therapeutics
1.2$6.19-3.4%$112.73 millionN/A0.00News Coverage
MRAC
Marquee Raine Acquisition
0.0$9.85-0.5%$108.36 millionN/A0.00
EEIQ
Elite Education Group International
0.0$5.27-0.9%$46.38 millionN/A0.00Gap Down
Presidio Property Trust logo
SQFT
Presidio Property Trust
0.3$3.29-4.9%$32.56 millionN/A0.00High Trading Volume
News Coverage
Gap Down
IGNY
Ignyte Acquisition
0.0$9.86-0.5%$19.12 millionN/A0.00News Coverage
AFAQU
AF Acquisition
0.0$9.99-0.3%$0.00N/A0.00
ANEB
Anebulo Pharmaceuticals
0.0$7.08-0.4%$0.00N/A0.00
ANZUU
Anzu Special Acquisition Corp I
0.0$9.96-0.0%$0.00N/A0.00
ATSPU
Archimedes Tech SPAC Partners
0.0$10.00-0.0%$0.00N/A0.00
ARRWU
Arrowroot Acquisition
0.0$9.98-0.2%$0.00N/A0.00
AUUD
Auddia
0.0$2.50-4.0%$0.00N/A0.00
BRIVU
B. Riley Principal 250 Merger Corp. Units
0.0$9.99-0.1%$0.00N/A0.00
BSA
BrightSphere Investment Group
0.0$25.17-1.2%$0.00N/A0.00
CPZ
Calamos Long/Short Equity & Dynamic Income Term Trust
0.0$20.46-1.4%$0.00N/A0.00
CMLTU
CM Life Sciences III
0.0$10.81-0.8%$0.00N/A0.00High Trading Volume
Quiet Period Expiration
CRZNU
Corazon Capital V838 Monoceros
0.0$10.00-0.0%$0.00N/A0.00
DKDCU
Data Knights Acquisition Corp. Unit
0.0$10.09-0.2%$0.00N/A0.00
DCRCU
Decarbonization Plus Acquisition Corp III
0.0$10.02-0.0%$0.00N/A0.00
DLY
DoubleLine Yield Opportunities Fund
0.0$19.78-0.1%$0.00N/A0.00
EBACU
European Biotech Acquisition
0.0$10.00-0.0%$0.00N/A0.00
EVOJ
Evo Acquisition
0.3$9.77-0.1%$0.00N/A0.00
FRSGU
First Reserve Sustainable Growth
0.0$9.99-0.1%$0.00N/A0.00
FMIVU
Forum Merger IV
0.0$9.97-0.3%$0.00N/A0.00News Coverage
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.